<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03922633</url>
  </required_header>
  <id_info>
    <org_study_id>E3112-CP2</org_study_id>
    <nct_id>NCT03922633</nct_id>
  </id_info>
  <brief_title>A Single Intravenous Dose of E3112 in Japanese Healthy Adult Male Participants</brief_title>
  <official_title>A Phase 1 Clinical Study of a Single Intravenous Dose of E3112 in Japanese Healthy Adult Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EA Pharma Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics after&#xD;
      a single intravenous dose of E3112 in Japanese healthy adult male participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 22, 2019</start_date>
  <completion_date type="Actual">October 1, 2020</completion_date>
  <primary_completion_date type="Actual">May 20, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Serum Concentrations of E3112</measure>
    <time_frame>Day 1: 0-24 hours; Day 8: 0-24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Baseline in Serum Concentration of E3112</measure>
    <time_frame>Day 1: 0-24 hours; Day 8: 0-24 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Concentration (Cmax) of E3112</measure>
    <time_frame>Day 1: 0-24 hours; Day 8: 0-24 hours</time_frame>
    <description>Cmax is the maximum observed concentration that a drug achieves in a specified compartment or test area of the body after the drug has been administered.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Peak Concentration (Tmax) of E3112</measure>
    <time_frame>Day 1: 0-24 hours; Day 8: 0-24 hours</time_frame>
    <description>Tmax is the time from dosing to reach the maximum observed concentration a drug achieves in a specified compartment or test area of the body after the drug has been administered.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve (AUC 0-t) of E3112</measure>
    <time_frame>Day 1: 0-24 hours; Day 8: 0-24 hours</time_frame>
    <description>AUC 0-t is area under the concentration-time curve from time 0 to time of last quantifiable concentration for E3112.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Concentration-time Curve (AUC∞) of E3112</measure>
    <time_frame>Day 1: 0-24 hours; Day 8: 0-24 hours</time_frame>
    <description>AUC∞ is area under the concentration-time curve from time 0 to infinity of E3112.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Half-life of Elimination (t1/2) of E3112</measure>
    <time_frame>Day 1: 0-24 hours; Day 8: 0-24 hours</time_frame>
    <description>t1/2 is the time required for the concentration of the drug to reach half of its original value.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clearance (CL) of E3112</measure>
    <time_frame>Day 1: 0-24 hours; Day 8: 0-24 hours</time_frame>
    <description>CL is defined as the rate of drug elimination divided by the plasma concentration of the drug.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Volume of Distribution (Vd) of E3112</measure>
    <time_frame>Day 1: 0-24 hours; Day 8: 0-24 hours</time_frame>
    <description>Vd is the theoretical volume that would be necessary to contain the total amount of an administered drug at the same concentration that it is observed in the blood plasma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with an Abnormal, Clinically Significant Hematology parameter value</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with an Abnormal, Clinically Significant Clinical Chemistry Parameter Value</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with an Abnormal, Clinically Significant Urine Value</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Change in Vital Signs</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Change in Electrocardiogram (ECG)</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Change in Physical Findings</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Clinically Significant Change in Ophthalmological Findings</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Serum Anti-E3112 Antibodies</measure>
    <time_frame>Day 1 to Day 43</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Male Participants</condition>
  <arm_group>
    <arm_group_label>Cohort 1 Group A: E3112 + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1 Group B: Placebo + E3112</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Group A: E3112 + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2 Group B: Placebo + E3112</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 Group A: E3112 + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3 Group B: Placebo + E3112</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 Group A: E3112 + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>E3112 intravenous infusion in treatment stage 1 followed by placebo intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 Group B: Placebo + E3112</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo intravenous infusion in treatment stage 1 followed by E3112 intravenous infusion in treatment stage 2. A washout period of 7 days will be maintained between the two treatment stages.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>E3112</intervention_name>
    <description>Intravenous infusion.</description>
    <arm_group_label>Cohort 1 Group A: E3112 + Placebo</arm_group_label>
    <arm_group_label>Cohort 1 Group B: Placebo + E3112</arm_group_label>
    <arm_group_label>Cohort 2 Group A: E3112 + Placebo</arm_group_label>
    <arm_group_label>Cohort 2 Group B: Placebo + E3112</arm_group_label>
    <arm_group_label>Cohort 3 Group A: E3112 + Placebo</arm_group_label>
    <arm_group_label>Cohort 3 Group B: Placebo + E3112</arm_group_label>
    <arm_group_label>Cohort 4 Group A: E3112 + Placebo</arm_group_label>
    <arm_group_label>Cohort 4 Group B: Placebo + E3112</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intravenous infusion.</description>
    <arm_group_label>Cohort 1 Group A: E3112 + Placebo</arm_group_label>
    <arm_group_label>Cohort 1 Group B: Placebo + E3112</arm_group_label>
    <arm_group_label>Cohort 2 Group A: E3112 + Placebo</arm_group_label>
    <arm_group_label>Cohort 2 Group B: Placebo + E3112</arm_group_label>
    <arm_group_label>Cohort 3 Group A: E3112 + Placebo</arm_group_label>
    <arm_group_label>Cohort 3 Group B: Placebo + E3112</arm_group_label>
    <arm_group_label>Cohort 4 Group A: E3112 + Placebo</arm_group_label>
    <arm_group_label>Cohort 4 Group B: Placebo + E3112</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Non-smoking Japanese males aged 20 to 44 years at the time of written, informed&#xD;
             consent&#xD;
&#xD;
          2. Body Mass Index (BMI) at screening is 18.5 or more but less than 25.0 kilogram per&#xD;
             square metre (kg/m^2)&#xD;
&#xD;
          3. Written, informed consent to participate in the study based on the participant's own&#xD;
             free will&#xD;
&#xD;
          4. Willing and able to comply with the requirements in the study after being fully&#xD;
             informed of the requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Male participants with reproductive potential who and whose partner do not agree to&#xD;
             practice medically appropriate contraception (Note: throughout the study)&#xD;
&#xD;
          2. A history or complication of malignant tumor, lymphoma, leukemia, or&#xD;
             lymphoproliferative disorder, a clinically significant disease requiring treatments&#xD;
             within 8 weeks before the investigational product treatment, or a history of a&#xD;
             clinically significant infection within 4 weeks before the investigational product&#xD;
             treatment&#xD;
&#xD;
          3. With a psychiatric, digestive, hepatic, renal, respiratory, endocrine, hematologic,&#xD;
             neural, or cardiovascular disease within 4 weeks before the investigational product&#xD;
             treatment, a congenital metabolic abnormality, or otherwise a disease that may affect&#xD;
             the drug assessments&#xD;
&#xD;
          4. With a surgical history (e.g., resection of the liver, kidney, or digestive tract,&#xD;
             etc.) at screening that may affect the pharmacokinetics of the investigational product&#xD;
&#xD;
          5. Suspicion of having a clinically abnormal symptom or an organ impairment that requires&#xD;
             treatments based on the history/complications at screening or physical findings, vital&#xD;
             signs, electrocardiogram findings, or laboratory values at screening or baseline&#xD;
&#xD;
          6. Testing positive for human immunodeficiency virus (HIV) at screening&#xD;
&#xD;
          7. A positive response to a qualitative test for hepatitis B virus surface antigen (HBs&#xD;
             antigen), hepatitis B virus core antigen (HBc) antibody, hepatitis C virus (HCV)&#xD;
             antibody, or syphilis&#xD;
&#xD;
          8. Use of a prescription drug within 4 weeks before the investigational product treatment&#xD;
&#xD;
          9. Use of an over-the-counter drug within 2 weeks before the investigational product&#xD;
             treatment&#xD;
&#xD;
         10. Receiving a vaccine within 4 weeks before the investigational product treatment&#xD;
&#xD;
         11. Ongoing participation in another clinical study or use of an investigational product&#xD;
             or device within 16 weeks before the investigational product treatment while&#xD;
             participating in another clinical study&#xD;
&#xD;
         12. Receiving blood transfusion within 12 weeks before the investigational product&#xD;
             treatment, providing a whole-blood sample of 400 millilitre (mL) or more between 12 to&#xD;
             4 weeks before the investigational product treatment or a whole-blood sample of 200 mL&#xD;
             or more within 4 weeks before the investigational product treatment, or giving blood&#xD;
             components by pheresis within 2 weeks before the investigational product treatment&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>EA Pharma Trial Site</name>
      <address>
        <city>Higashi</city>
        <state>Fukuoka</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 16, 2019</study_first_submitted>
  <study_first_submitted_qc>April 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 22, 2019</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>E3112</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Japanese</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

